IMMUTEP

Immutep completed subject enrolment in Phase II of AIPAC-003 trial for eftilagimod alpha (efti) in breast cancer, involving 65 patients with HR+, HER2-/low, or triple-negative breast cancer. Participants were randomized to receive 30mg or 90mg of efti plus paclitaxel, aiming to determine the optimal biological dose (OBD) for Phase III. The trial includes an open-label Phase II followed by a double-blind, placebo-controlled Phase III.

Global LAG-3 Inhibitors Market expected to exceed USD 3 billion by 2029; Opdualag, first LAG-3 therapy, approved for melanoma. LAG-3 inhibitors show potential in combination therapies for various cancers and diseases. Key players include Bristol Myers Squibb, Roche, and Regeneron. Market valued at USD 625 million in 2023, projected to grow significantly.

Global LAG-3 inhibitors market to exceed USD 3 billion by 2029, driven by the approval of Opdualag, the first LAG-3 therapy, and ongoing clinical trials evaluating LAG-3 inhibitors in combination therapies. Key players include Bristol Myers Squibb, Symphogen A/S, and Hoffmann-La Roche.

Immutep completes patient enrolment in Phase II of AIPAC-003 trial for metastatic breast cancer patients, randomising 65 patients to receive eftilagimod alpha with paclitaxel at 30mg or 90mg doses.

Immutep to present new EFTISARC-NEO Phase II data at CTOS 2024, evaluating efti, radiotherapy, and KEYTRUDA® in soft tissue sarcoma. Initial results show deep responses in first six patients.

EFTISARC-NEO trial results of efti, radiotherapy, and KEYTRUDA® to be presented at CTOS 2024. First trial to evaluate efti in neoadjuvant setting for soft tissue sarcoma, showing promising initial efficacy. STS has high unmet medical need and poor prognosis.